Physician profile
John Paul Ott
NPI 1841342912
$3,972.91
in general payments reported to CMS, 2019-2025
24 companies · $51.01 in 2025
The $51.01 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $555 · 2021: $478 · 2022: $404 · 2023: $228 · 2024: $484 · 2025: $51.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,438.74 | 2019-2024 | Rybelsus, Ozempic |
| Allergan, INC. | $626.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $344.66 | 2019-2024 | Airsupra |
| Abbvie INC. | $270.35 | 2019-2024 | |
| Amgen INC. | $212.86 | 2019-2024 | Otezla, Enbrel |
| Ucb, INC. | $212.12 | 2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $185.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $159.24 | 2019 | |
| Pfizer INC. | $91.41 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $85.29 | 2020-2025 | Acthar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.59 | 2019-2020 | |
| Janssen Biotech, INC. | $53.79 | 2024 | Tremfya |
| Amarin Pharma, INC. | $30.36 | 2019-2020 | |
| Ibsa Pharma INC. | $28.04 | 2019 | |
| Ani Pharmaceuticals, INC. | $25.86 | 2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.66 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.60 | 2019 | |
| Eisai INC. | $18.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2019 | |
| Currax Pharmaceuticals LLC | $16.81 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.73 | 2019 | |
| Shire North American Group INC | $13.35 | 2019 | |
| Merck Sharp & Dohme LLC | $11.46 | 2019 | |
| Endo Pharmaceuticals INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.